Value of chemotherapy for patients with locoregional breast cancer recurrence

Liz Meszaros, MDLinx

San Antonio Breast Cancer Symposium 2017

San Antonio, Texas, United States | December 05-09, 2017


Although chemotherapy can positively impact patient outcomes after locoregional recurrence of breast cancer, this will generally occur only in patients with HR-negative (HR-) disease rather than those with HR-positive (HR+) disease, according to William Gradishar, MD, professor of medicine, Northwestern University, Evanston, IL.

Dr. Gradishar stressed, however, that even in patients with HR- disease, data on th effects of chemotherapy are limited, but suggest that HR- patients who undergo chemotherapy will demonstrate improved disease-free survival, and possibly better overall survival.

In HR-positive disease, chemotherapy does not seem to have any effect, he added.

“We have to individualize and be selective about where we use chemotherapy,” Dr. Gradishar concluded.